Is there any Relationship Between Eosinophilia Myalgia Syndrome (Ems) and Fibromyalgia Syndrome (Fms)? an Analysis Of Clinical and Immunological Data
The eosinophilia-myalgia syndrome (EMS) caused by intake of contaminated L-tryptophan resembles in its clinical presentation the fibromyalgia syndrome (FMS). We, therefore, analysed clinical and immunological parameters in 16 patients with chronic EMS and 100 patients with FMS in order to see whether there may be a relationship between both disorders. From 12 FMS patients and 12 controls also peripheral blood mononuclear cells (PBMC) were obtained. Myalgia and arthralgia was observed in chronic EMS in the same incidence as in patients with FMS (81%). Also antibodies to serotonin, gangliosides and phospholipids were present in both groups. In vitro stimulation of PBMC with different L-tryptophan preparations revealed in six of the 12 FMS patients but only two of the control individuals a production of type 2 cytokines (IL-5, IL-10). We, therefore, conclude that EMS may have developed in patients suffering primarily from FMS as an allergic reaction towards a more immunogenic L-tryptophan preparation.
Unable to display preview. Download preview PDF.
- Belongia E.A., Hedberg C.W., Gleich G.J., White K.E., Mayeno A.M., Loegering D.A., Dunnette S.L., Pirie PL., MacDonald K.L., and Osterholm MT., 1990, An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N. Engl. J. Med. 323:357–365.PubMedCrossRefGoogle Scholar
- Klein R. and Berg P.A., 1995, High incidence of antibodies to 5-hydroxytryptamine, gangliosides and phospholipids in patients with chronic fatigue and fibromyalgia syndrome and their relatives: Evidence for a clinical entity of both disorders, European Journal of Medical Research 1:21–26.PubMedGoogle Scholar
- Mosmann T.R., Schumacher J.H., Fiorentino D.F., Leverah J, Moore K.W., and Bond M.W, 1990, Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new Th2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid solid phase radioimmunoadsorbent assay. J. Immunol. 145:2938–2945.PubMedGoogle Scholar
- Yamaguchi Y., Hayashi Y., Sugama Y., Miura Y., Kasahara T., Kitamura S., Torisu M., Mita S., Tominaga A., and Takatsu K., 1988, Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. Il-5 as an eosinophil chemotactic factor, J. Exp. Med. 167:1737–1742.PubMedCrossRefGoogle Scholar